CTLA4 and melanoma: New prognostic factors are needed to assess the risk for each patient and to determine the best treatment option, especially among the new and recently validated therapeutic options in stage IV melanoma, such as: (i) single anti-PD1 immunotherapy versus combination with anti-CTLA4 immunotherapy [1]; (ii) first-line targeted therapy versus first-line immunotherapy in BRAF-mutated melanoma [2,3].